- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06831552
Een gerandomiseerde fase II-studie-evaluatie van de toevoeging van de resource-interventie om het eigen vermogen (stijging) te ondersteunen aan de gebruikelijke ondersteunende zorg voor kinderen met nieuw gediagnosticeerd neuroblastoom met een hoog risico (RISE in HR NBL)
The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity [Pediatric RISE]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes.
Participants will be randomized to receive one of the following for 6-months:
- Usual supportive care alone or
- Usual supportive care plus Pediatric RISE
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This is a randomized Phase II trial evaluating the addition of the RISE supportive care equity intervention to usual supportive care for poverty-exposed children participants with newly diagnosed high-risk neuroblastoma. Participants will be randomized into one of two groups: Usual supportive care or Pediatric RISE plus usual supportive care. Randomization means a participant is placed into a study group by chance.
The research study procedures include screening for eligibility, in-person or virtual appointments, and surveys.
Participation in this research study is expected to last for about 6-months.
It is expected that about 84 participants will take part in this research study.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Kira Bona, MD, MPH
- Telefoonnummer: 617-632-4688
- E-mail: Kira_Bona@dfci.harvard.edu
Studie Locaties
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Werving
- Children's Hospital Colorado
-
Contact:
- Katherine Lind, MD
- E-mail: Katherine.Lind@childrenscolorado.org
-
Contact:
- Navin Pinto, MD
- E-mail: Navin.Pinto@childrenscolorado.org
-
-
Connecticut
-
Hartford, Connecticut, Verenigde Staten, 06106
- Werving
- Connecticut Children's Medical Center
-
Contact:
- Andrea Orsey, MD, MSCE
- Telefoonnummer: 860-545-9630
- E-mail: aorsey@connecticutchildrens.org
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30329
- Werving
- Children's Healthcare of Atlanta
-
Contact:
- Thomas Cash, MD
- Telefoonnummer: 404-785-1200
- E-mail: william.cash@choa.org
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 03079
- Werving
- Dana-Farber Cancer Institute
-
Contact:
- Kira Bona, MD, MPH
- Telefoonnummer: 203-464-9417
- E-mail: kira.bona@childrens.harvard.edu
-
-
New York
-
New York, New York, Verenigde Staten, 10027
- Werving
- Columbia University Medical Center
-
Contact:
- Melissa Beauchemin, MD
-
Contact:
- Justine Kahn, MD
- E-mail: jk2034@cumc.columbia.edu
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45229
- Werving
- Cincinnati Children's Hospital Medical Center
-
Contact:
- Katherine Somers, MD
- E-mail: katherine.somers@cchmc.org
-
Contact:
- Meera Kotagal, MD
- E-mail: meera.kotagal@cchmc.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- Children's Hospital of Philadelphia
-
Contact:
- Rochelle Bagatell, MD
- Telefoonnummer: 267-426-9737
- E-mail: bagatellr@chop.edu
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75390
- Werving
- University of Texas Southwestern Medical Center
-
Contact:
- Puja Umaretiya, MD
- Telefoonnummer: (214) 456-2382
- E-mail: puja.umaretiya@utsouthwestern.edu
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98105
- Werving
- Seattle Children's Hospital
-
Contact:
- Anurekha Hall, MD
- Telefoonnummer: 206-987-2106
- E-mail: anurekha.hall@seattlechildrens.org
-
Contact:
- Kristine Karvonen, MD
- E-mail: Kristine.Karvonen@seattlechildrens.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Patient cohort: The randomized Phase II multi-center RISE intervention will be conducted among a population of poverty-exposed children with high-risk neuroblastoma. Poverty will be a priori defined as parent-reported low-income (<200% Federal Poverty Level). Children receiving treatment for cancer at study sites will serve as the study cohort, with parents/guardians as survey informants and intervention recipients on behalf of their minor children given that parents (not children) typically manage household finances.
- Patient newly diagnosed with high-risk neuroblastoma
- Patient has established care at study site and initiated cancer-directed therapy
- Patient has not yet initiated Induction Cycle 3
- Patient aged 0-17 years at the time of consent
- Parent/guardian screened positive for self-reported low-income (<200% Federal Poverty) *
- Family primary residence in MA, PA, IL, CA, WA, CT, GA, WI and OH
- Both patients co-enrolled on ANBL2131 or those receiving standard of care therapy at their center are eligible to participate
- Patients of all languages are eligible to participate
Exclusion Criteria:
- Foreign national family receiving care as an Embassy-pay patient.
- Child or household member receiving SSI
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm 1: RISE Intervention + Usual Supportive Care
Participants will be randomized in a 1:1 ratio and stratified according to treatment group and Household Material Hardship (HMH) severity score. Participant parents/guardians will complete:
|
Income-poverty targeted, supportive care intervention that includes direct cash transfers delivered by the Fund for Guaranteed Income, a non-profit organization, along with benefits counseling to discuss the risk of means-tested benefits loss or reduction. Funds will be dispersed to families via debit card or through personal banking, PayPal, or Venmo on a twice monthly basis for a total of twelve disbursements (6-months). Meetings with a benefits counselor will be conducted by the HIPAA-compliant video conference platform, Zoom.
Andere namen:
|
|
Geen tussenkomst: Arm 2: Usual Supportive Care
Participants will be randomized in a 1:1 ratio and stratified according to treatment group and HMH severity score. Participant parents/guardians will complete:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Household Material Hardship (HMH) Score Reduction Rate
Tijdsspanne: Baseline (T1) and 6-months (end-intervention; T3)
|
HMH score reduction rate is defined as the proportion of patients achieving at least 1 domain reduction in (food, housing, utility or transportation insecurity). HMH scores range from 0 to 4, with scores of 0 indicating no hardship (unexposed) and scores of 1-4 indicating the presence of hardship (exposed). Patients who are unexposed to HMH at baseline (HMH score of 0) are excluded from the analysis. |
Baseline (T1) and 6-months (end-intervention; T3)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pediatric-Modified Comprehensive Score for Financial Toxicity (COST)
Tijdsspanne: 3-months (end-of-induction; T2) and 6-months (end-intervention; T3)
|
Financial toxicity will be assessed with the 12-item modified COST measure. Each item is rated on a 0-4 scale, yielding a total score range of 0-48, with higher scores indicating better financial well-being. The final COST score will be calculated per established methods. A change of approximately 5 points is considered a minimally important difference (MID), representing a clinically meaningful change in financial toxicity. |
3-months (end-of-induction; T2) and 6-months (end-intervention; T3)
|
|
Parent Psychological Distress (Kessler-6) Score Change from Baseline to 6 Months
Tijdsspanne: Baseline (T1) and 6-months (end-intervention; T3)
|
Psychological distress will be assessed using the 6-item Kessler-6 scale. The scale includes 6 items scored from 0 ('none of the time') to 4 ('all of the time'), yielding a total score ranging from 0 to 24, with higher scores indicating greater psychological distress. A reduction in scores of approximately 2.8 points is considered a minimally important difference (MID), representing a clinically meaningful improvement in psychological distress. |
Baseline (T1) and 6-months (end-intervention; T3)
|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Abilities Score Change from Baseline to 6 Months
Tijdsspanne: Baseline (T1) and 6-months (end-intervention; T3)
|
The PROMIS Applied Cognition-Abilities short form is an 8-item measure assessing subjective learning and memory, attention and concentration, executive function, and processing speed. Responses are scored on a scale of 1-5, and the total score is converted to a T-score with a mean of 50 and a standard deviation (SD) fixed at 10. Higher scores suggest better perceived cognitive function. |
Baseline (T1) and 6-months (end-intervention; T3)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Kira Bona, MD, MPH, Dana-Farber Cancer Institute
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata
- Neoplasmata per histologisch type
- Neoplasmata, glandulair en epitheel
- Neoplasmata, neuro-epitheliaal
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Neuro-ectodermale tumoren, primitief, perifeer
- Neuro-ectodermale tumoren, primitief
- Neuroblastoom
Andere studie-ID-nummers
- 24-600
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Dr. Kira Bona. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD-tijdsbestek voor delen
Data can be shared no earlier than 1 year following the date of publication
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .